Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
1. A method comprising:
receiving a stool sample from a healthy donor at a central location, wherein the donor has been prescreened for infectious agents;
placing the stool sample within a stool collection device;
mixing the stool sample with a liquid to form a mixture, wherein the liquid comprises a buffer and a cryoprotectant;
homogenizing and filtering the mixture to separate fiber from bacteria and produce a filtrate comprising a substantially entire microbiota of the stool sample.
2. The method of claim 1 , wherein said the cryoprotectant is selected from the group consisting of glycerol, polyethylene glycol, trehalose, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, and a combination thereof.
3. The method of claim 1 , wherein the cryoprotectant comprises trehalose.
4. The method of claim 1 , wherein the filtrate further comprises an antioxidant.
5. The method of claim 1 , wherein the filtrate further comprises cysteine.
6. The method of claim 1 , wherein the method further comprises lyophilizing the filtrate.
7. The method of claim 6 , wherein the method further comprises encapsulating the lyophilized filtrate into a carrier.
8. The method of claim 7 , wherein the carrier is selected from the group consisting of a tablet, a geltab, a pill, and a capsule.
9. The method of claim 1 , wherein the method further comprises freezing the filtrate.
10. The method of claim 1 , wherein the method further comprises encapsulating the filtrate.
11. The method of claim 10 , wherein the encapsulated filtrate is frozen for storage.
12. The method of claim 10 , wherein the encapsulated filtrate is in an graded release capsule.
13. The method of claim 1 , wherein the stool collection device is sterile and sealed.
14. The method of claim 1 , wherein the mixture, the filtrate, or both are maintained in an at least 95% oxygen free environment.
15. The method of claim 1 , wherein the method further comprises adding one or more cultured bacteria to the filtrate.
16. The method of claim 1 , wherein the method comprises recurrent filtration with decreasing filter sizes.
17. A method comprising:
receiving a stool sample from a healthy donor at a central location, wherein the donor has been prescreened for infectious agents;
placing the stool sample within a stool collection device;
mixing the stool sample with a liquid to form a mixture, wherein the liquid comprises a buffer, a cryoprotectant, and an antioxidant;
homogenizing and filtering the mixture to produce a filtrate comprising an antioxidant and a substantially entire microbiota of the stool sample, wherein the filtering results in separation of fiber from the microbiota.
18. The method of claim 17 , wherein said the cryoprotectant is selected from the group consisting of glycerol, polyethylene glycol, trehalose, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, and a combination thereof.
19. The method of claim 17 , wherein the cryoprotectant comprises trehalose.
20. The method of claim 17 , wherein the filtrate comprises cysteine.
21. The method of claim 17 , wherein the method further comprises lyophilizing the filtrate.
22. The method of claim 21 , wherein the method further comprises encapsulating the lyophilized filtrate into a carrier.
23. The method of claim 22 , wherein the carrier is selected from the group consisting of a tablet, a geltab, a pill, and a capsule.
24. The method of claim 17 , wherein the method further comprises freezing the filtrate.
25. The method of claim 17 , wherein the method further comprises encapsulating the filtrate.
26. The method of claim 25 , wherein the encapsulated filtrate is frozen for storage.
27. The method of claim 25 , wherein the encapsulated filtrate is in an graded release capsule.
28. The method of claim 17 , wherein the stool collection device is sterile and sealed.
29. The method of claim 17 , wherein the mixture, the filtrate, or both are maintained in an at least 95% oxygen free environment.
30. The method of claim 17 , wherein the method further comprises adding one or more cultured bacteria to the filtrate.
31. The method of claim 17 , wherein the method comprises recurrent filtration with decreasing filter sizes.